Addressing Knowledge Gaps and Clinical Challenges of PSMA PET in Prostate Cancer
UroToday – GU OncToday brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and urology.
UroToday – GU OncToday brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and urology.
APCCC 2024, prostate cancer, Prostate-Specific Membrane Antigen Ligand Positron Emission Tomography (PSMA-PET), 18F-PSMA-1007, 68Ga-PSMA-11, imaging modalities in the setting of early recurrent prostate cancer, rib…
APCCC 2024, alternative PSMA Ligands, 68Ga-PSMA-11, 18F-DCFPyL, 18F-PSMArh7.3, 18F-PSMA-1007, benign bone uptake, PSMA-617, PSMA-I&T, SPOTLIGHT trial, 18F-PSMArh7.33, UCLA/UCSF trial, CONDOR trial.
APCCC 2024, metastatic castration resistant prostate cancer (mCRPC), PSMA radioligand therapy, Docetaxel, cabazitaxel, 177Lu-PSMA-617, TROPIC trial, CARD trial, TAX327 trial, SWOG 9916 trial, PRESIDE trial,…
At the 2024 UCSF-UCLA PSMA Conference, Oliver Sartor advocates for the early use of PSMA radioligand therapy in prostate cancer treatment, challenging the traditional reliance…
Were you unable to attend APCCC 2024? Get all of the groundbreaking research, new guidelines, and the latest advances in urologic medicine you missed.
APCCC 2024, prostate cancer, Lancet Commission on Prostate Cancer, prostate cancer population, worldwide prostate cancer cases, prostate cancer future outlook, global prostate cancer disparity.
Scientists at Scripps Research have developed atomic-level structural models of enzymes linked to autoimmune and inflammatory conditions, such as lupus and Alzheimer’s disease. When nucleic…
Congress did nothing this spring to rein in how pharmacy benefit managers operate, and the PBM industry spent big to get that result, new disclosures…
APCCC 2024, prostate cancer, PARP Inhibitors, Side Effects of PARP Inhibitors, PARP inhibitor monotherapy trials, MAGNITUDE trial, PROpel trial, TALAPRO-2 trial, PARP inhibitor hematological side…
At the 2024 UCSF-UCLA PSMA Conference, Matthew Rettig discusses the critical advancements and challenges in treating metastatic castration-resistant prostate cancer (mCRPC), highlighting the shift towards…